PFSA
HEALTHCAREProfusa Inc
$0.49-0.03 (-6.48%)PRE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving PFSA Today?
No stock-specific AI insight has been generated for PFSA yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$0.41$412.50
$0.49
Fundamentals
Market Cap$2M
P/E Ratio—
EPS$-107.01
Dividend Yield—
Dividend / Share—
ROE—
Profit Margin—
Debt / Equity—
Trading
Volume430K
Avg Volume (10D)—
Shares Outstanding4.4M
PFSA News
22 articles- Profusa Receives Favorable Nasdaq Listing DeterminationGlobeNewswire Inc.·May 8, 2026
- Profusa Initiates Board-Led Process to Evaluate Strategic Alternatives and Maximize Shareholder ValueYahoo Finance·May 5, 2026
- What's Going On With Profusa Stock Tuesday?Benzinga·Apr 7, 2026
- Profusa Stock Soars On Deal Targeting Multi Billion Precision Diagnostics SpaceBenzinga·Apr 6, 2026
- Profusa Expands into Multi-Billion Dollar Precision Diagnostics Market with $30M Letter of Intent for a PanOmics PlatformYahoo Finance·Apr 6, 2026
- Profusa To Withdraw S-1 Registration Statement to Pursue a Smaller, More Focused OfferingYahoo Finance·Feb 27, 2026
- Profusa Receives Purchase Orders for Lumee™ Tissue Oxygen Monitoring and Raises 2026 Revenue GuidanceYahoo Finance·Feb 19, 2026
- Profusa and Mayo Clinic collaborate to Advance High-Impact Clinical Applications of Oxygen Monitoring TechnologiesYahoo Finance·Feb 13, 2026
- Profusa Announces 1-for-75 Reverse Stock SplitYahoo Finance·Feb 5, 2026
- Profusa Presents Positive US-Study Clinical Results at Leipzig Interventional Course (LINC) 2026Yahoo Finance·Jan 29, 2026
- Profusa Launches Lumee™ Tissue Oxygen Healthcare Research Offerings, Initiating First Commercial RevenueYahoo Finance·Jan 16, 2026
- Profusa Adds Leading Greek Vascular Surgeon to Customer BaseYahoo Finance·Jan 8, 2026
- Profusa Bolsters European Commercial Network with New French Distributor, MedSellYahoo Finance·Dec 31, 2025
- Profusa Restructures Senior Secured Convertible Notes, Only Convertible Above $0.35Yahoo Finance·Dec 30, 2025
- Profusa U.S. Study Met Primary End Points as Presented at Late Breaking Clinical Trials at Paris Vascular Insights 2025Yahoo Finance·Dec 15, 2025
- Profusa to Present US-Study Clinical Data at Leipzig Interventional Course (LINC) 2026Yahoo Finance·Dec 11, 2025
- Profusa to Present Late Breaking U.S.-Based Clinical Trial Update at Paris Vascular Insights 2025Yahoo Finance·Nov 24, 2025
- Profusa Announces Third Quarter Business and Financial HighlightsYahoo Finance·Nov 19, 2025
- Profusa Outlines Potential Path to $250 Million Revenue by 2030, Driven by Sequential Lumee™ Oxygen and Glucose Monitoring LaunchesYahoo Finance·Oct 30, 2025
- Profusa Completes Manufacturing Build-Out, On Track to Begin Product Shipments and Revenue in Early 2026Yahoo Finance·Oct 28, 2025
- Profusa Expands Sales Footprint with New Distributor for Lumee™ Oxygen Platform in EuropeYahoo Finance·Oct 22, 2025
- Profusa Adds a Leading French Critical Limb Ischemia Surgeon to Customer BaseYahoo Finance·Oct 1, 2025
All 22 articles loaded
Price Data
Open$0.53
Previous Close$0.52
Day High$0.55
Day Low$0.52
52 Week High$412.50
52 Week Low$0.41
52-Week Range
$0.41$412.50
$0.49
Fundamentals
Market Cap$2M
P/E Ratio—
EPS$-107.01
Dividend Yield—
Dividend / Share—
ROE—
Profit Margin—
Debt / Equity—
Trading
Volume430K
Avg Volume (10D)—
Shares Outstanding4.4M
About Profusa Inc
Profusa, Inc. develops bioengineered sensors that are designed to become one with the body to detect and continuously transmit clinical -grade data for personal and medical use. The company is headquartered in Emeryville, California.
Listed July 14, 2025
HEALTHCAREMEDICAL DEVICES
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICMEDICAL DEVICES
CIK—
Composite FIGI—
Share Class FIGI—